NAT1 catalyzes both N- and O-acetylation reactions. These reactions are essential for the detoxification of a wide range of drugs and environmental carcinogens. The enzyme helps in the metabolism of heterocyclic and arylamine substrates, which are often found in various pharmaceuticals and environmental toxins . Additionally, NAT1 is involved in folate catabolism, which is vital for cellular function and DNA synthesis .
NAT1 has been implicated in the bioactivation of several known carcinogens. Genetic polymorphisms in the NAT1 gene can lead to variations in enzyme activity, which may influence an individual’s susceptibility to certain cancers, such as colon and urinary bladder cancers . High levels of NAT1 activity have been linked to an increased risk of these cancers due to the enzyme’s role in activating carcinogenic compounds .
Recombinant NAT1 refers to the enzyme produced through recombinant DNA technology. This involves inserting the NAT1 gene into a suitable expression system, such as bacteria or yeast, to produce the enzyme in large quantities. Recombinant NAT1 is used in various research applications to study its function, mechanism, and role in drug metabolism and carcinogenesis .
NAT1 is predominantly expressed in the cytoplasm and cytosol of cells . It is highly expressed in tissues such as the bronchial epithelial cells, mucosa of the ileum, colon, and nasopharynx . The enzyme’s expression pattern suggests its significant role in the metabolism of inhaled and ingested xenobiotics.